{"id":11252,"date":"2019-06-18T00:00:00","date_gmt":"2019-06-18T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/congres-annuel-2019-de-l-european-hematology-association\/"},"modified":"2025-08-19T08:28:21","modified_gmt":"2025-08-19T13:28:21","slug":"congres-annuel-2019-de-l-european-hematology-association","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2019\/06\/18\/congres-annuel-2019-de-l-european-hematology-association\/","title":{"rendered":"CONGR\u00c8S ANNUEL 2019 DE L&rsquo; EUROPEAN HEMATOLOGY ASSOCIATION"},"content":{"rendered":"<p>Nous revenons tout juste du congr\u00e8s annuel 2019 de l\u2019EHA (European Hematology Association&nbsp;), au cours duquel la professeure Maria-Victoria Mateos (Universit\u00e9 de Salamanque, Espagne) a discut\u00e9 d\u2019\u00e9tudes remarquables sur le my\u00e9lome multiple.Elle a pr\u00e9sent\u00e9 les r\u00e9sultats prometteurs du premier volet de l\u2019\u00e9tude CASSIOPEIA portant sur l\u2019ajout du daratumumab \u00e0 la combinaison bort\u00e9zomib-thalidomide-dexam\u00e9thasone (D-VTd) comparativement \u00e0 la combinaison VTd chez les patients atteints d\u2019un my\u00e9lome multiple nouvellement diagnostiqu\u00e9 qui sont admissibles \u00e0 une greffe. Elle a \u00e9galement discut\u00e9 de certaines des conclusions importantes des \u00e9tudes FORTE et GEM-CESAR, et a termin\u00e9 sa pr\u00e9sentation en parlant de l\u2019\u00e9tude ELOQUENT-3 dans le cas de rechutes et de l\u2019\u00e9tude COLUMBA.&nbsp;<\/p>\n<p><a href=\"https:\/\/ecancer.org\/video\/8027\/myeloma-highlights-from-eha-2019.php\" target=\"_blank\" rel=\"noopener\">Visionnez la vid\u00e9o<\/a> (en anglais)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nous revenons tout juste du congr\u00e8s annuel 2019 de l\u2019EHA (European Hematology Association&nbsp;), au cours duquel la professeure Maria-Victoria Mateos (Universit\u00e9 de Salamanque, Espagne) a discut\u00e9 d\u2019\u00e9tudes remarquables sur le my\u00e9lome multiple.Elle a pr\u00e9sent\u00e9 les r\u00e9sultats prometteurs du premier volet de l\u2019\u00e9tude CASSIOPEIA portant sur l\u2019ajout du daratumumab \u00e0 la combinaison bort\u00e9zomib-thalidomide-dexam\u00e9thasone (D-VTd) comparativement \u00e0 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53,50,58,52],"tags":[],"class_list":["post-11252","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-news-events","category-nouvelles-de-myelome-canada","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11252","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11252"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11252\/revisions"}],"predecessor-version":[{"id":31328,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11252\/revisions\/31328"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11252"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11252"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11252"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}